Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/101177
Title: | Management of ibrutinib treatment in patients with B-cell malignancies: clinical practice in Portugal and multidisciplinary recommendations | Authors: | Carda, José Pedro Santos, Lurdes Mariz, José Mário Monteiro, Pedro Gonçalves, Humberto Miguel Raposo, João Silva, Maria Gomes da |
Keywords: | B-cell malignancies; Bruton tyrosine kinase inhibitor; ibrutinib; recommendations | Issue Date: | Dec-2021 | Project: | The project received financial support from Janssen for logistics of expert meetings and editorial support. | Serial title, monograph or event: | Hematology (United Kingdom) | Volume: | 26 | Issue: | 1 | Abstract: | Ibrutinib, a potent inhibitor of the Bruton tyrosine kinase, has revolutionized the treatment of many B-cell malignancies. Ibrutinib has an established favorable toxicity profile with up to 8 years of experience in clinical trials; however, despite ibrutinib's favorable toxicity profile, dose reductions and treatment discontinuations are becoming more evident in clinical practice, particularly in the setting of specific clinical contexts and patient characteristics. This manuscript is set to provide practical recommendations on the management of patients treated with this agent in daily practice. | URI: | https://hdl.handle.net/10316/101177 | ISSN: | 1607-8454 | DOI: | 1607-8454 34605364 10.1080/16078454.2021.1980690 34605364 1607-8454 |
Rights: | openAccess |
Appears in Collections: | I&D ICBR - Artigos em Revistas Internacionais |
Files in This Item:
SCOPUSTM
Citations
2
checked on Sep 23, 2024
WEB OF SCIENCETM
Citations
2
checked on Sep 2, 2024
Page view(s)
85
checked on Sep 25, 2024
Download(s)
130
checked on Sep 25, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License